Craft

Aditx Therapeutics

Stock Price

$0.6

2024-10-29

Market Capitalization

$3.3 M

2024-10-29

Revenue

$3.2 K

FY, 2025

Aditx Therapeutics Summary

Company Summary

Overview
Aditx Therapeutics is a company that aims to develop DNA-based technologies to minimize the rejection of transplanted organs in humans. It works on ADi products for organ transplantation, skin grafting, autoimmune diseases, allergies, and further indications, with the initial focus on skin allografts and psoriasis.
Type
Public
Status
Active
Founded
2017
HQ
Mountain View, CA, US | view all locations
Website
https://aditxt.com/
Cybersecurity rating
Sectors

Key People

  • Amro Albanna

    Amro Albanna, Co-founder and Chief Executive Officer

  • Shahrokh Shabahang

    Shahrokh Shabahang, Co-founder and Chief Innovation Officer

  • David Briones

    David Briones, Chief Financial Officer

LocationsView all

1 location detected

  • Mountain View, CA HQ

    United States

    2569 Wyandotte St #101

Aditx Therapeutics Financials

Summary Financials

Revenue (Q1, 2026)
$12.2K
Gross profit (Q1, 2026)
$2.9K
Net income (Q1, 2026)
($16.2M)
Cash (Q1, 2026)
$268.9K
EBIT (Q1, 2026)
($4.4M)
Enterprise value
$7.3M

Footer menu